Das Bild zeigt rechts ein Trichterglas mit blauer Flüssigkeit und Glasstab zum Umrühren. Daneben steht ein Reagenzglasständer mit Reagenzgläsern, die ebenfalls blaue Flüssigkeit enthalten. Im Hintergrund ist ein Forscher zu sehen, der in der rechten Hand eine Pipette hält.

EUGeneHeart

You are here:

EUGeneHeart - Genomics of hypertrophic signalling to treat and prevent heart failure

EU, PI: VRZ, 2005 - 2011,

Partners: Belgium, Italy, Hungary, UK, Netherlands, Sweden

Congestive heart failure is a leading cause of cardiovascular morbidity and mortality and is the main cause of hospitalization among patients older than 65 years in Europe. Coronary heart disease, hypertension, diabetes, smoking, and hyperlipoproteinemia, are major causes for heart failure in older patients. However, it remains unknown whether women are more susceptible to heart failure than men. The molecular mechanisms for the transition from cardiac hypertrophy to heart failure (and cardiac death) are currently not understood. Accordingly, it is the goal of this project to develop new strategies to prevent and treat heart failure by understanding the genomics of hypertrophic and heart failure signalling. Specifically, our aims are as follows:

1) To break down and identify beneficial and harmful aspects of hypertrophic signalling

2) In patient cohorts, we will identify genetic polymorphisms representing susceptibility factors for the development of hypertrophy and modifying factors which predispose for progression into heart failure

3) To develop new strategies to inhibit detrimental and promote beneficial signals of the hypertrophic program

4) To develop training programs for scientists and technicians

5) To collaborate with European Societies, National programs and patient organizations to increase the knowledge of experts and the lay population regarding heart failure treatment and prevention.

Contact person for the EUGeneHeart Project